Shuwen Biotech Co. Ltd., a China-based diagnostic company focused on licensing, developing and commercializing diagnostic kits and services for unmet clinical needs, has announced that the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to its China-based clinical laboratories Shuwen Guanz Diagnostic Lab Co., Ltd. based on results of a recent on-site inspection as part of the CAP’s Accreditation Programs.
“We are delighted to have received CAP accreditation,” said Saaras Hu, Chief Operating Officer of Shuwen Guanz Diagnostic Lab Co., Ltd. “As a leading clinical diagnostic reference lab in China, we strive to maintain the highest quality standard and provide the best diagnostic services to our customers. CAP accreditation attests our effort.”
Jay Z. Zhang, Chairman and CEO of Shuwen Biotech Co. Ltd. added: “We have provided clinical testing services to Chinese physicians. We have also provided companion diagnostic development services to pharmaceutical companies. CAP accreditation is a validation of our molecular diagnostic capabilities and allows us to expand our services internationally in clinical testing for both hospitals and pharmaceutical companies.”
The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal-to or more-stringent-than the government’s own inspection program.
During the CAP accreditation process, designed to ensure the highest standard of care for all laboratory patients, inspectors examine the laboratory’s records and quality control of procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management.
Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.